Richard I. Christopherson

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Method for B Cell Receptor Enrichment in Malignant B Cells.

Method for B Cell Receptor Enrichment in Malignant B Cells.

Journal: Cancers

Published: April 02, 2024

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.

Journal: Leukemia & lymphoma

Published: January 16, 2024

The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.

The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.

Journal: Leukemia & lymphoma

Published: November 07, 2023

Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies.

Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies.

Journal: Cancers

Published: April 19, 2023

Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.

Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.

Journal: Nucleosides, nucleotides & nucleic acids

Published: December 10, 2021

Adenylated proteins in mouse B16-F10 melanoma cells cluster in functional categories: a new paradigm for cellular regulation?

Adenylated proteins in mouse B16-F10 melanoma cells cluster in functional categories: a new paradigm for cellular regulation?

Journal: Nucleosides, nucleotides & nucleic acids

Published: November 05, 2021

The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.

The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.

Journal: EJHaem

Published: July 14, 2020

IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.

IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.

Journal: Blood advances

Published: December 19, 2019

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: December 04, 2019

Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.

Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.

Journal: Leukemia & lymphoma

Published: January 17, 2019

Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.

Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.

Journal: Leukemia & lymphoma

Published: June 19, 2018

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.

Journal: British journal of haematology

Published: March 08, 2018

Showing 1-12 of 42

Last Updated: 09/26/2026